Gilteritinib Superior in Relapsed, Refractory FLT3 - Mutated AML

Overall survival significantly longer, percentage of remission higher than with salvage chemotherapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news